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1. Indroduction 
Many healthcare workers are concerned about the risk of occupational exposures to 
hazardous drugs. Since Falck [Falck et al.,1979] reported that mutagens were detected in the 
urine samples of nurses involved in chemotherapy, many reports have been published 
about the presence of urinary mutagen [Roth et al.,1994; Burgaz et al.,1999; Kasuba et 
al.,1999; Lanza et al.,1999; Jakab et al.,2001; Kopjar & Garaj-Vrhovac,2001], and about the 
detection of unchanged hazardous drugs in the urine samples of healthcare workers [Hirst 
et al.,1984; Sessink et al.,1992, 1994, 1995; Ensslin et al.,1994; Minoia et al.,1998; Burgaz et 
al.,1999; Pethran et al.,2003]. Tomioka [Tomioka & Kumagai,2005] monitored occupational 
exposures to hazardous drugs by routes of exposures and the levels at which the drugs exert 
their effects; i.e. (i) external exposures, exposure to airborne drugs and drugs deposited on 
the working table; (ii) internal exposures, presence of drugs or their metabolites in blood 
and urine; (iii) cellular level effects, presence of mutagens in urine and frequency of sister 
chromatid exchanges; and (iv) effects on individual level, susceptibility to cancer and effects 
on reproduction. Recent improvements of analytical instruments have permitted direct 
monitoring of external exposures and internal exposures. 
Hospital pharmacists in Japan have been required to prepare chemotherapeutic drugs. The 
Japanese Society of Hospital Pharmacists (JSHP) revised the “Guideline for the Handling of 
Antineoplastic Drugs in Hospitals” in 2005, and recommended standard precautionary 
measures for using the laminar flow cabinet, masks, gloves, caps, disposable nonwoven 
clothes, and luer-lok syringes. This guideline was based on the “NIOSH alert” by the 
National Institute for Occupational Safety and Health [NIOSH,2004]. In addition, the JSHP 
investigated occupational exposures to cyclophosphamide in several hospitals, and reported 
that internal exposures and external exposures varied greatly in individuals, in hospitals 
and even in countries. This investigation led to increased concerns among hospital 
pharmacists about the exposures to chemotherapeutic drugs. 
Before the JSHP investigation, we have investigated whether the precautionary measures we 
took were adequate to prevent occupational exposures [Ikeda et al.,2007; Maeda et al.,2010]. 
We focused on occupational exposures to epirubicin, cyclophosphamide and ifosfamide, 
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and reported that the surfaces of biological safety cabinets (BSCs) and ambient 
environments were contaminated by these drugs during preparation by pharmacists 
(external exposures). However, detection frequencies and amounts of these drugs were low 
levels, compared with previous reports in Japan [Nabeshima et al.,2008; Yoshida et al.,2009]. 
In addition, no drugs were detected in sera and urine samples of healthcare workers 
involved in chemotherapy (internal exposures). Thus, we concluded that adequate 
precautionary measures and improved awareness regarding handling of chemotherapeutic 
drugs could reduce the risk of occupational exposures. These investigations were focused on 
specific drugs, however, a progress of chemotherapy increases amounts of and varieties of 
chemotherapeutic drug uses. Thus, more versatile methods are desired. 
Multicomponent analyses are useful for monitoring environmental contaminations, such as 
pesticide chemicals [Lissalde et al.,2011; Miao et al.,2011] and air pollution [Skoczynska et 
al.,2008; Sebok et al.,2009]. However, there are only several reports in the fields of 
occupational exposures to healthcare workers [Larson et al.,2003; Sabatini et al.,2005; Sottani 
et al.,2007, 2008; Nussbaumer et al.,2010]. 
In this paper, we used liquid chromatography-mass spectrometry/mass spectrometry (LC-
MS/MS) and developed multicomponent analysis procedures for chemotherapeutic drugs, 
and assessed the levels of environmental contaminations involved in preparation of 
chemotherapeutic drugs. We selected ten kinds of drugs mainly used in chemotherapy; 
cyclophosphamide, ifosfamide, epirubicin, doxorubicin, vindesine, vincristine, vinblastine, 
irinotecan, docetaxel and paclitaxel. Classification of drugs, chemical natures, regulations, 
uses of drugs, side effects, carcinogenicities, cytotoxicities [Goolsby & Lombardo,2006] and 
pregnancy categories of each drug were summarized in Table 1. 
 
No. Name of drugs Regulations 
Classification of drugs 
(chemical natures) 
Main uses of drugs 
1 Vindesine 
Powerful 
drug 
Vincalkaloid  
(antimicrotuble drug) 
Leulemia, Lung cancer 
2 Vincristine 
Powerful 
drug 
Vincalkaloid  
(antimicrotuble drug) 
Leukemia, Malignant lymphoma, 
Multiple myeloma 
3 Vinblastine 
Powerful 
drug 
Vincalkaloid  
(antimicrotuble drug) 
Malignant lymphoma, Urothelial 
carcinome 
4 Doxorubicin 
Powerful 
drug 
Anthracycline  
(anticancerous antibiotic) 
Malignant lymphoma, Breast 
cancer, Lung cancer 
5 Epirubicin 
Powerful 
drug 
Anthracycline  
(anticancerous antibiotic) 
Leukemia, Malignant lymphoma, 
Breast cancer 
6 Ifosfamide 
Powerful 
drug 
Mustard (alkylating drug) Lung cancer, Prostatic cancer 
7 Cyclophosphamide 
Powerful 
drug 
Mustard (alkylating drug) 
Leukemia, Breast cancer, 
Rheumatism 
8 Irinotecan 
Powerful 
drug 
Topoisomerase I inhibitor 
Lung cancer, Ovarian cancer, 
Colorectal cancer 
9 Docetaxel Toxicant 
Taxane  
(antimicrotuble drug) 
Breast cancer, Lung cancer, 
Uterine cancer 
10 Paclitaxel Toxicant 
Taxane  
(antimicrotuble drug) 
Breast cancer, Lung cancer, 
Uterine cancer 
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No. Name of drugs Main side effects 
Hazard potential 
 
Carcinogenicity Cytotoxicity Pregnancy 
1 Vindesine Myelosuppression   Vesicant 
 
2 Vincristine 
Peripheral neuropathy, 
Cardiotoxicity  
Vesicant Category D 
3 Vinblastine Myelosuppression 
 
Vesicant Category D 
4 Doxorubicin 
Delayed myelosuppression 
and cardiotoxicity 
Probably 
carcinogenic 
Vesicant Category D 
5 Epirubicin 
Delayed myelosuppression 
and cardiotoxicity  
Vesicant Category D 
6 Ifosfamide Hemorrhagic cystitis 
 
Irritant Category D 
7 Cyclophosphamide 
Myelosuppression, 
Hemorrhagic cystitis 
Carcinogenic Irritant Category D 
8 Irinotecan 
Delayed diarrhea, 
Myelosuppression  
Non-
vesicant 
Category D 
9 Docetaxel 
Myelosuppression, Pulmonary 
fibrosis  
Vesicant Category D 
10 Paclitaxel 
Myelosuppression, Perepheral 
neuropathy 
  Vesicant Category D 
Regulations, use of drugs and side effects were authorized by the Ministry of Health, Labour and 
Welfare in Japan. 
Carcinogenicities were classified by IARC monographs on the evaluation of the carcinogenic risk of 
chemicals to humans. 
Pregnancy categories were classified by U.S. Department of Health and Human Services Food  
and Drug Administration. Category D was "there is positive evidence of human fetal risk  
based on adverse reaction data from investigational or marketing experience or studies in  
humans, but potential benefits may warrant use of the drug in pfegnant women despite potential  
risks." 
Table 1. Charactaristics of selected chemotherapeutic drugs. 
2. Materials and methods 
2.1 Chemicals and materials 
Doxorubicin, ifosfamide, cyclophophamide and paclitaxel were purchased from Wako Pure 
Chemical (Osaka, Japan). 3,4-Anhydro vincristine [internal standard (IS) 1] was purchased 
from Toronto Research Chemicals (Toronto, Canada). Camptothecin (IS 2) was purchased 
from Tokyo Chemical Industry (Tokyo, Japan). Docetaxel, carminomycin (IS 3) and 
trofosfamide (IS 4) were purchased from Santa Cruz Biotechnology (California, USA). 
Irinotecan and cephalomannine (IS 5) were purchased from Sigma-Aldrich (Missouri, USA). 
Vincristine, vinblastine and epirubicin were kindly provided by Nippon Kayaku. Vindesine 
was kindly provided by Shionogi. Acetonitrile and methanol (LC-MS chromasolv) were also 
purchased from Sigma-Aldrich (Missouri, USA), and formic acid was purchased from Wako 
Pure Chemicals. 
2.2 Preparation of stock solutions, working solutions and calibration standards 
Vindesine was prepared in a solution of 0.1% formic acid-water to obtain a final 
concentration of 2 mg/ml. Camptothecin was prepared in a solution of 0.1% formic acid-
methanol to obtain a final concentration of 100 g/ml. Other drugs were prepared in a 
www.intechopen.com
 
Environmental Contamination 
 
84
solution of 0.1% formic acid-methanol to obtain a final concentration of 2 mg/ml. Aliquots 
of these solutions were stored at -80°C, then diluted in 0.1% formic acid-methanol to obtain 
a final concentration of 100 g/ml each stock solution and stored at -30°C. 
Stock solutions of three vincalkaloids were mixed to working solutions, containing 33.3 
g/ml of vindesine, vincristine and vinblastine, respectively. Stock solutions of other seven 
drugs were also mixed and diluted in 0.1% formic acid-methanol to working solutions, 
containing 5 g/ml of doxorubicin, epirubicin, ifosfamide, cyclophosphamide, irinotecan, 
docetaxel and paclitaxel, respectively. The working solutions of internal standard mixtures 
were prepared by containing 100 g/ml of 3,4-anhydro vincrisitine, and containing 10 
g/ml of carminomycin, trofosfamide, camptothecin and cephalomannine, respectively. 
These working solutions were also stored at -30°C. We used black Eppendorf tubes for stock 
solutions of anthracycline drugs and vincalkaloid drugs, and for all working solutions. 
The calibration standards were prepared by diluting these working solutions. 
2.3 Chromatographic conditions 
An Alliance 2695 HPLC separation module (Waters; Massachusetts, USA) with PDA 
detector, cooled autosampler and column oven was used to perform this monitoring. 
Chromatographic separation was achieved on an octadecyl silyl column (Inertsil® ODS-3; 50 
mm×2.1 mm; particle size, 3 m; GL Sciences, Tokyo, Japan) with a guard column (cartridge 
guard-column E®; 20 mm×2.0 mm; particle size, 3 m, GL Sciences, Tokyo, Japan). Column 
oven was maintained at 30°C and autosampler was maintained at 5°C. The mobile phases 
consisted of 0.1% formic acid-water (mobile phase A) and acetonitrile (mobile phase B). A 
flow rate was 0.3 ml/min and gradient elution was performed in the following manner: 15% 
of mobile phase B to 45% over 10 min; 45% of mobile phase B to 80% over 7 min. 
Subsequently, the concentration of mobile phase B was linearly decreased to 15% for 1 min 
and equilibrated for 4 min. Total run time was 22 min. 
2.4 Mass spectrometry conditions 
A tandem quadrupole MS TQD (Waters; Massachusetts, USA), operated in multiple reaction 
monitoring (MRM) in positive electrospray ionization (ESI) mode, was used for detection 
and MassLynx 4.1 software was used for data acquisition and processing. MS/MS 
parameters (precursor ion, product ion, cone energy, collision energy and retention time) of 
each drug were individually optimized by QuanOptimize software and syringe pump 
infusion in primary mobile phase by constant flow (Table 2). 
2.5 Precautionary measures and personals involved in preparation of 
chemotherapeutic drugs 
Precautionary measures were based on “NIOSH alert” [NIOSH,2004] and “Guidelines for 
the Handling of Antineoplastic Drugs in Hospitals” by JSHP (Table 3). A preparation area 
for outpatient chemotherapy was selected as an environmental monitoring. The numbers of 
person involved in preparation for outpatients were eight; six men and two women, and 
ages were from twenty-four to forty-one. We rotated schedules regularly, and limited 
successive preparation time to 1 hour. 
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Parameters  Precersor 
ion 
Product 
ion 
Cone  
energy (V) 
Collision  
energy (V) 
Retention 
time (min) 
Compounds       
Vindesine  754.5  124.2  55 50 1.65  
Vincristine  825.4  765.6  70 40 5.02  
Vinblastine  811.4  224.1  60 45 5.75  
3,4-Anhydro vincristine (IS 1) 807.4  747.5  65 30 6.22  
       
Doxorubicin  544.5  397.2  20 12 6.18  
Epirubicin  544.5  397.2  20 12 6.60  
Carminomycin (IS 2)  514.2  307.2  20 25 8.29  
       
Ifosfamide  261.0  153.9  45 25 7.21  
Cyclophosphamide  261.0  140.3  45 30 7.63  
Trofosfamide (IS 3)  323.1  153.9  30 25 12.69  
       
Irinotecan  587.7  167.3  60 45 5.77  
Camptothecin (IS 4)  349.1  305.2  50 25 9.51  
       
Docetaxel  808.8  226.1  20 14 15.95  
Paclitaxel  854.8  286.3  25 24 16.48  
Cephalomannine (IS 5)  832.8  264.2  25 20 16.09  
Table 2. Parameters of MS/MS analysis. 
 
No Precautionary measures 
  
1 Prepare chemotherapeutic drugs in a centralized area restricted to authorized 
personnel with expertise in the preparatory techniques and the characteristics of these 
drugs. 
2 Prepare these drugs in a biological safety cabinet Class II Type B. 
3 Place a superabsorbent sheet on the surfaces of the preparation cabinets. 
4 Use syringes with Luer-Lok-type fittings for preparing these drugs. 
5 Use gowns made of a lint-free, low-permeability fabric.The gown should have a closed 
front, long sleeves, and elastic or knit-closed cuffs. 
6 Use disposable nitrile rubbers gloves doubly, and change gloves every hour or on 
accidental exposures. 
7 Wear disposable mask and cap. 
8 Remove protective clothing carefully to avoid spreading contaminations. 
9 Maintain a negative pressure in the drug vials. 
10 Always close the cover of trash boxes used to dispose of these drugs. 
These measures are based on the NIOSH alert, and we take measure No. 3 for additional precaution.  
Table 3. Precautionary measures we took. 
2.6 Sampling procedures of ambient environment 
We collected wiping samples from the surfaces of the BSCs and from the surfaces of the 
tables inside a separated area and outside one (Fig. 1). Investigations were carried out as 
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soon as daily preparation for outpatients had finished and before daily cleaning-up 
procedures, and obtained samples were immediately extracted and measured by LC-
MS/MS equipments. We took this monitoring on seven days for successive two weeks. 
 
C
sink
A
A
shelf
BSC
chair
A
A
BSC
B
B
B
C
C
C
C
a separeted area
 
Fig. 1. Photograph of a preparation area (inside a separated area) for outpatients 
chemotherapy, and floor layout of a preparation area and sampling spots. A) Surfaces of the 
BSCs, B) Surfaces of the tables inside a separated area, C) Surfaces of the tables outside a 
separated area. 
An extraction of wiping samples for environmental assessments was modified by our 
previous report [Maeda et al.,2010]. Briefly, we first applied internal standards mixtures, 
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containing 10 g of 3,4-anhydro vincrisitine, 500 ng of carminomycin, trofosfamide, 
camptothecin and cephalomannine to sampling spots. After these spots were air-dried, we 
wiped 800 cm2 area (20 cm×40cm) with a sheet of Kimwipe® S-200 (120 mm×215mm, 
Nippon Paper Crecia, Tokyo, Japan) wetted with 1 ml of 0.1% formic acid-70% methanol. 
We repeated wiping operation twice, then placed both sheets in light-blocking 
polypropylene conical tubes and added 8 ml of 0.1% formic acid-70% methanol. We shook 
these tubes for 30 min, 2,000 rotations per min. Obtained extracts were directly injected into 
LC-MS/MS equipments without dilution. 
3. Results 
All drugs were clearly detected and quantified over a total run time of 22 min.  
The calibration curves were fitted by the linear regression 5-1000 ng/wipe for 
doxorubicin, epirubicin, ifosfamide, cyclophosphamide, irinotecan and paclitaxel, 10-1000 
ng/wipe for docetaxel, and 100-10000 ng/wipe for vindesine, vincristine and  
vinblastine, respectively. 
Table 4 showed the positive ratio of detection and amounts of detected drugs. The surfaces 
of the BSCs were occasionally contaminated, meanwhile, contaminations in the surfaces of 
the tables inside a separated area and outside one were at low levels. 
 
Sampling spots A) Surfaces  
of the BSCs 
B) Surfaces of the tables  
inside a separated area 
C) Surfaces of the 
tables outside a 
separated area 
Compounds Positive 
samples 
(n = 28) 
Amounts  
(ng/wipe) 
Positive samples 
(n = 14) 
Amounts  
(ng/wipe) 
Positive 
samples 
(n = 14) 
Amounts  
(ng/wipe) 
Vindesine 0  ―  0  ―  0  ― 
Vincristine 0  ―  0  ―  0  ― 
Vinblastine 0  ―  0  ―  0  ― 
         
Doxorubicin 5  7 ~ 114  0  ―  0  ― 
Epirubicin 0  ―  0  ―  0  ― 
         
Ifosfamide 0  ―  1  7   0  ― 
Cyclophosphamide 9  5 ~ 68  1  21   1  7  
         
Irinotecan 0  ―  0  ―  0  ― 
         
Docetaxel 3  9 ~ 348  0  ―  0  ― 
Paclitaxel 1  19   1  14   0  ― 
Table 4. Frequencies and amounts of drugs detected in wipe samples. 
4. Discussion 
Since Falck’s report [Falck et al.,1979], many healthcare workers are concerned about the 
risk of occupational exposures to hazardous drugs. Previously, in studies of external 
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exposures [Sessink et al.,1992; Minoia et al.,1998; Sabatini et al.,2005; Hedmer et al.,2008] and 
studies in internal exposures [Hirst et al.,1984; Sessink et al.,1992, 1994, 1995; Ensslin et 
al.,1994; Burgaz et al.,1999; Pethran et al.,2003], cyclophosphamide was frequently used as a 
marker of occupational exposures because of its slight volatility and human genotoxicity 
[Connor et al.,2000], reproductive toxicity [Anderson et al.,1995], carcinogenicity 
[IARC,1981], and ease of detection [Turci et al.,2002; Barbieri et al.,2006].  
We also focused on occupational exposures to several chemotherapeutic drugs including 
cyclophosphamide, and concluded the precautionary measures we took were adequate to 
prevent occupational exposures [Ikeda et al.,2007; Maeda et al.,2010]. 
In this paper, because a progress of chemotherapy requires more versatile monitoring, we 
developed a multicomponent analysis method of chemotherapeutic drugs, and assessed the 
levels of environmental contaminations involved in preparation of chemotherapeutic drugs. 
Anthracycline drugs were light sensitive and were absorbed on glass containers [Lachatre et 
al.,2000] and vincalkaloid drugs were absorbed on some materials of tubes [Van Tellingen et 
al.,1991], we selected black Eppendorf tubes for stock solutions and working solutions, and 
light-blocking polypropylene tubes through extraction. 
We prepare chemotherapeutic drugs in three different ways; (i) prepare drugs for 
outpatients on the BSCs equipped on a separated area, maintained constant a negative 
pressure, in hospital pharmacy; (ii) prepare drugs for inpatients on the BSCs equipped on a 
separated area in hospital pharmacy; (iii) prepare drugs for inpatients required special care 
(such as pretreatment for hematopoietic stem cell transplantation) on the BSCs equipped at 
the corner of the nurse station in a biological clean ward. We focused on environment of 
preparation for outpatients, because numbers of drugs were prescribed for outpatients and 
fast preparations were needed. 
Our multicomponent analysis method had sufficient sensitivities and had conveniences 
enough for regular monitoring. Lower limits of quantitation were 5 ng/wipe for 
doxorubicin, epirubicin, ifosfamide, cyclophosphamide, irinotecan and paclitaxel, 10 
ng/wipe for docetaxel, and 100 ng/wipe for vindesine, vincristine and vinblastine, 
respectively. 
In the environmental assessments, vindesine, vincrisitine, vinblastine, epirubicin and 
irinotecan were not detected. Although doxorubicin, cyclophosphamide, docetaxel and 
paclitaxel were occasionally detected in the surfaces of the BSCs, frequencies and amounts 
of drugs detected were low levels in the surfaces of the working tables inside a separated 
area and outside one. 
Inhalation and dermal penetration were presumed to be the main routes of occupational 
exposures. Several researchers [McDevitt et al.,1993; Sessink et al.,1994; Minoia et al.,1998] 
compared the urinary cyclophosphamide excretion levels and concentrations of 
cyclophosphamide in air during preparation of drugs. They concluded that the amounts of 
cyclophosphamide inhaled were much lower than amounts of cyclophsphamide excreted in 
urine, and that inhalation was not the main route of exposures resulting in high levels of 
cyclophosphamide. Fransman [Fransman et al.,2004, 2005] reported that dermal exposure 
predominantly occurred on the hands and sporadically on the forehead and forearms, and 
he mentioned that greater than 90% exposures were prevented by using latex gloves at the 
time of preparations. These reports showed that dermal exposures occurred on the hands 
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were the main route of internal exposures. Thus, routine monitoring of unexpected 
environmental contaminations is very useful for preventing occupational exposures.  
5. Conclusion 
We developed a multicomponent analysis method of ten major chemotherapeutic drugs, 
and assessed the levels of environmental contaminations involved in preparation of 
chemotherapeutic drugs. We revealed that environmental contaminations outside BSCs 
were at low levels, and concluded that adequate precautionary measures and improved 
awareness regarding handling of chemotherapeutic drugs could reduce the risk of 
occupational exposures. 
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